// App-Quantinova.ai

: Human CD39 overexpression or APT102 recombinant apyrase administration enhances Treg and Tr1 cell immunity in inflammatory bowel disease

Researchers

Presenter

  • Marta Vuerich

Principal Investigators

  • Rene J. Robles

  • Samiran Mukherjee

  • Anyan Xie

  • Rasika Harshe

  • Alan C. Moss

  • Simon C. Robson

  • Maria Serena Longhi

Medical Centers

  • Beth Israel Deaconess Med Cntr

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

  • Blood/haematological Diseases

  • Autoimmune (AI)

  • Cardiovascular (CVS)

  • Genetic Disorder

  • Pulmonary/Respiratory Diseases

Disease

  • Ischemia-reperfusion injury

  • Inflammatory bowel disease

  • Crohn's disease

  • Venous thrombosis

  • Coronary Artery Disease

  • Ulcerative colitis

Biomarkers

  • Regulatory T cells

Drug/Treatment

  • dextran sulfate sodium

  • Deferoxamine

  • Adenosine

  • Adenosine Intravenous

  • Dex-HEMA

  • APT-102

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved